Lieber Schizophrenia Research Clinic


The Lieber Schizophrenia Research Clinic (LSRC) is located at the New York State Psychiatric Institute on the Columbia-Presbyterian Medical Campus. To enroll in the LSRC an individual will need to participate in research studies. The LSRC provides state-of-the-art outpatient evaluation and clinical treatment for individuals suffering with schizophrenia, schizoaffective disorder, or new onset psychotic disorder.

Treatment services provided include: full psychiatric evaluation, individual medication management visits with a clinic psychiatrist, and weekly group therapy. Patients and their families are also invited to participate in the Multiple Family Group (MFG), an educational support group, run in conjunction with the Center for Family Education and Research (CFER). Patients are only responsible for the cost of their medications.

Goal of the LSRC:

To answer a wide range of questions about the nature and causes of schizophrenia and its treatment through a multi-faceted research program. The clinic's ability to follow patients over time will help to develop a more comprehensive knowledge base about schizophrenia. An increased understanding will facilitate the development of more effective treatments for this illness.

Click here for Clinical Trials

Contact information

Beatriz Alvarez, MA.
Clinical Research Coordinator

New York State Psychiatric Institute
1051 Riverside Drive, Unit 2
New York, NY 10032

Ph: 212-543-5418 Fax: 212-543-5537
E-mail: alvarez@pi.cpmc.columbia.edu

Roberto Gil, M.D.
LSRC Director

New York State Psychiatric Institute
1051 Riverside Drive, Unit 2
New York, NY 10032

Ph: 212-543-6190 Fax: 212-543-5537
E-mail: gilrobe@pi.cpmc.columbia.edu

Criteria for Admission:

The LSRC staff will consider admitting only those individuals who are willing to participate in research and whom they feel will benefit from the evaluation and treatment provided. The following criteria must be met for consideration:

18-65 years of age
No significant medical problems
No drug or alcohol use disorders
No recent history of significant violence or self-injurious behavior
Ability to give informed consent for the research procedures
If you are currently not taking medication and are determined to be clinically stable
by the treatment team, you may be asked to remain off of medication for up to 3 weeks




Website designed by the: Web Design Studio


@2005 Columbia University Department of Psychiatry
180 Ft. Washington Avenue, New York, NY 10032